Powered by OpenAIRE graph
Found an issue? Give us feedback

RTU

Riga Technical University
Country: Latvia
Funder (2)
Top 100 values are shown in the filters
Results number
arrow_drop_down
84 Projects, page 1 of 17
  • Funder: EC Project Code: 898858
    Overall Budget: 152,202 EURFunder Contribution: 152,202 EUR

    The biomaterials are crucial for the surgical remediation of bone defects caused by various diseases e.g. osteoporosis and traumatic fractures. However, there are several risks associated with this treatment; first, the surgical procedure itself carries a potential risk of inflammation and bone infection, second, the bone replacement can fail requiring revision surgery. In fact, the host immune response to implanted materials and devices is the main factor that will determine a long-term functional outcome of the biomaterial mediated treatment. Therefore, the bone biomaterial ability to modulate the local immune environment for favorable treatment outcomes has to be considered. The usage of bioactive metabolites has emerged as one of the most novel and potent approach for immune response modulation. The incorporation of metabolites with immune regulatory properties seems an especially attractive option for biomaterials as it would ensure site-specific delivery system and allow modulation of the microenvironment. The goal of this project is to develop novel biomaterials with incorporated metabolites as a potentially effective and safe strategy to modulate local immune response towards favorable outcomes of surgical bone remediation. To achieve it, the recent concept of metabolomics with the state of the art biomaterial design and research will be combined in this project. This proposal includes the transfer of knowledge to the host institution and the training of the researcher in new techniques and skills. The multidisciplinary nature of the project is strong, combining materials science, biochemistry, and molecular biology. Results have the potential to pave the way for novel biomaterials significantly improving clinical outcomes for patients suffering from bone injuries.

    more_vert
  • Funder: EC Project Code: 101106882
    Funder Contribution: 162,499 EUR

    With increase of global dental implant industry, perimplantitis became an emerging problem worldwide, affecting up to 43% of the placed implants. Periimplantitis is caused by pathogenic microorganisms,that adhere to the implant surface triggering imflammation and bone destruction, eventally leading to implant loss in half of the cases. The overall aim of periimplantitis treatment is re-osteointegration of implant with surrounding bone, that can be achieved only in case of complete control over infection The existing treatment approaches are not able to provide efficient decontamination of the implant surfaces, while effectiveness of the existing local antibiotic delivery systems is questionable. The aim of this project is to develop biomimetic injectable CaP-based pastes with antibacterial and osteogenic properties for periimplantitis treatment. We will utilize biocompatible materials, such as octacalcium phosphate (OCP) and natural hydrogels (hyaluronic acid and functionalized gelatin) that closely resemble to the composition of inorganic and organic components of the bone extracellular matrix. They will serve as versatile platforms for local delivery of antibiotics such as Metronidazole and Doxyciсline or antimicrobial nanoparticles into the peri-implant pockets after mechanical removal of the bacterial biofilm. We hypothesize that these materials will offer control over infection in peri implant area and subsequent cellular functions and may have a great potential for implant re-osteointegration. To date, antibacterial formulations of bone graft materials, targeting peri-implant oral microflora are not available in the market. The obtained innovational products, designed according to the Principles of Good Manufacturing will have optimized composition and handling properties to be used straightforward at the chairside in dental office, without additional invasive surgical manipulations.

    more_vert
  • Funder: EC Project Code: 249306
    more_vert
  • Funder: EC Project Code: 797061
    Overall Budget: 133,904 EURFunder Contribution: 133,904 EUR

    The fifth generation (5G) cellular networks set ambitious goals that require technological advances in both wireless and transport network infrastructures, especially regarding cost and carbon footprint. In this context, a promising architecture for 5G aggregation networks is the recently proposed Claud-Radio Access Network (C-RAN). However, it will face the serious challenges related to (1) efficient use of network resources, (2) low-latency requirements, and (3) scalability. Seems that optical aggregation networks based on wavelength division multiplexing are the outstanding candidates to meet high-capacity and low-latency requirements. However, to reduce cost and power consumption, there has been a recent push towards the consolidation of the network by merging the access and metro transport where flexible-grid transmission is also considered. This becomes questionable in the context of the traditional C-RAN. Therefore, alternatives are being analysed including different function splits between cell-site and baseband equipment, and millimetre-wave carriers instead of optical carriers for interconnecting cell-site equipment and access central office. Hence, 5G-DRIVE project aims to explore the impact of transport cost and wireless channel (de-) aggregation technique on resource efficiency (cost, spectrum, power consumption) and service availability in aggregation network that uses optical or millimetre-wave carriers for interconnecting cell-site and baseband equipment.

    more_vert
  • Funder: EC Project Code: 952347
    Overall Budget: 899,960 EURFunder Contribution: 899,960 EUR

    Early stage researchers (ESR) from low performing countries are less competitive in the international scientific area than ESR's form internationally-leading counterparts. This is strongly related not only to the applicants itself, but also to the environment in which they were seeded as next generation researchers - meaning Universities. The competitiveness in scientific area is related to well measurable indicators, such as impact factors, papers in high-ranking journals, H-index, competitive funding, etc. Hence RISEus2 project´s Overall Objective is to significantly strengthen the research management and administration skills of RTU RBIDC leading staff and increase the research profile of ESR hosted in RTU RBIDC in the area of biomaterials development for bone tissue replacement and regeneration based on the long-term strategic cooperation between RTU RBIDC and three internationally leading counterparts: AO Research Institute Davos, Switzerland (ARI), Institut National Polytechnique de Toulouse CIRIMAT, France (INPT-CIRIMAT) and FORM-Lab Frankfurt Orofacial Regenerative Medicine, Goethe University Frankfurt, Germany (GUF). The purpose of RISEus2 is to create links and provide training which will ensure that RTU RBIDC will gain new knowledge and approaches of biomaterials research planning, implementation and exploitation. This will include methods, tools, equipment and effective infrastructure exploitation necessary to develop excellence in biomaterials research, that will boost the cooperation with the industry, thus becoming internationally competitive and attractive. The main RISEus2 activities include two way collaborative visits, mobility of staff, summer and winter schools, workshops at partner institutions, strengthening the visibility and cooperation with industry and intensive dissemination and outreach activities.

    more_vert
Powered by OpenAIRE graph
Found an issue? Give us feedback

Do the share buttons not appear? Please make sure, any blocking addon is disabled, and then reload the page.

Content report
No reports available
Funder report
No option selected
arrow_drop_down

Do you wish to download a CSV file? Note that this process may take a while.

There was an error in csv downloading. Please try again later.